uniQure's AMT-130 Regulatory Uncertainty Sparks Hope for Huntington’s Disease
TL;DR Summary
uniQure announced that the FDA no longer considers Phase I/II data versus an external control sufficient as primary evidence for a BLA submission for its Huntington's disease gene therapy AMT-130, creating uncertainty about the approval timeline. The company plans urgent discussions with the FDA and continues regulatory engagement in the EU and UK, despite holding breakthrough therapy and RMAT designations.
- uniQure (NASDAQ: QURE) updates on AMT-130; FDA feedback shifts, BLA timing unclear Stock Titan
- uniQure Provides Regulatory Update on AMT-130 for Huntington’s Disease Yahoo Finance
- Uniqure’s FDA submission for its Huntington’s disease therapy thrown into question statnews.com
- October 2025: This Month in Huntington’s Disease Research HDBuzz
- Hope for Huntington’s Sufferers God's World News
Reading Insights
Total Reads
0
Unique Readers
1
Time Saved
12 min
vs 13 min read
Condensed
98%
2,443 → 60 words
Want the full story? Read the original article
Read on Stock Titan